Do you want to volunteer for Clinical Trials? Register now

Volunteer for Clinical Trials

Have you ever thought about taking part in a Medical Trial? By registering your details with MedTrials.co.uk, we are able to send your details directly to companies who are looking for volunteers to take part in their medical research studies.

Information about you is kept on a register that CROs, Pharmaceutical companies and Clinical Investigators can access to contact you regarding individual studies.

Register now >

LifeArc, previously MRC Technology, to invest £500M

LifeArc, the U.K. medical research charity previously known as MRC Technology, announced plans to improve the lives of patients suffering from diseases that present the greatest challenges to medical research. By investing up to £500 million over the next five years, LifeArc will seek to generate, fund and champion innovations in antimicrobials, neuroscience, personalized oncology […]

The post LifeArc, previously MRC Technology, to invest £500M appeared first on CenterWatch News Online.

Powered by WPeMatico

News

Accenture joins Partnership on AI

Accenture has joined the Partnership on AI, an alliance of businesses, researchers, academics and policy makers that work to advance the understanding of artificial intelligence (AI) technology and develop best practices on the challenges and opportunities within the field. Accenture joins other prominent industry leaders who share its commitment to advancing the field of AI so […]

more >

AMRA, BioTelemetry partner on NASH/NAFLD clinical trials

AMRA, the international leader in body composition analysis, and BioTelemetry Research (BTR), a global imaging and cardiac core lab, announced the formation of an exclusive alliance for non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) clinical trials. This first-to-market partnership will advance imaging science and benefit clinical trial sponsors in several musculoskeletal and metabolic […]

more >

FDA approves CAR-T cell therapy for large B-cell lymphoma

The FDA approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. Yescarta, a chimeric antigen receptor (CAR) T cell therapy, is the second gene therapy approved by the […]

more >

Phase III Lusutrombopag study shows positive efficacy

Shionogi & Co. announced it will present positive efficacy and safety results from a global phase III study (L-PLUS 2) of lusutrombopag (S-888711), an investigational, once-daily, orally administered, small molecule thrombopoietin (TPO) receptor agonist, at the 2017 American Association for the Study of Liver Diseases (AASLD) Liver Meeting to be held October 20-24 in Washington, D.C. L-PLUS 2 […]

more >

Institut Curie, Pierre Fabre Partner on immuno-oncology

Institut Curie and the IRPF (Institut de Recherche Pierre Fabre) will collaborate on new therapeutic strategies to advance cancer treatment for patients. The objective of this novel partnership is to dissect the biology of novel therapeutically tractable targets and evaluate the impact of innovative pharmacological approaches leveraging the Institut Curie’s biological models. “We will work […]

more >

Type 2 diabetes: Blood sugar pill shows promise

In a 26-week phase II clinical trial for type 2 diabetes patients, glycemic control using semaglutide in pill form was better than using a placebo. Powered by WPeMatico

more >